文献速递贫血与红细胞疾病

通过调节嘌呤能信号减轻检查点抑制剂诱导的自身免疫性溶血性贫血

Mitigation of checkpoint inhibitor-induced autoimmune hemolytic anemia through modulation of purinergic signaling.
PubMed 文献 · Blood · 2024-01-01

该研究在小鼠模型中探讨免疫检查点抑制剂相关自身免疫性溶血性贫血(ICPi-AIHA)的细胞与分子机制。研究发现调节性T细胞(FoxP3+和Tr1)减少、炎症性Th17增加,并出现新型CD39+CD73-FoxP3-CD25-CD4+ T细胞亚群(CD39SP),早期CD39SP升高可预测AIHA发生;注射重组腺苷三磷酸双磷酸酶增强ATP酶活性可减轻AIHA。

要点

  • ICPi-AIHA小鼠模型出现自身抗体、溶血和死亡率增加,类似人类ICPi-AIHA特征。
  • CD39SP细胞早期升高可预测AIHA发生,CD39为分解ATP的胞外核苷酸酶。
  • 注射重组腺苷三磷酸双磷酸酶增强ATP酶活性可减轻AIHA及CD39SP减少。

核心结论

  • 研究揭示了ICPi-AIHA的细胞和分子机制,并提出了具有人类转化潜力的新诊断和治疗策略。

研究设计与样本

  • 研究采用新型小鼠模型,未明确报告样本量。

主要发现

  • ICPi-AIHA期间FoxP3+和Tr1调节性T细胞同时减少,炎症性Th17增加。
  • 出现新型CD39+CD73-FoxP3-CD25-CD4+ T细胞亚群(CD39SP),早期CD39SP升高预测AIHA发生。
  • 注射重组腺苷三磷酸双磷酸酶增强ATP酶活性可减轻AIHA发展和显著减少CD39SP。
  • CD39SP在多种发生AIHA的小鼠模型及AIHA患者中可检测到。
  • ICPi治疗的NZB小鼠狼疮发病加速且病情加重,包括AIHA;ICPi治疗健康B6动物可检测到CD39SP并产生针对多种自身抗原(包括红细胞和血小板)的自身抗体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICPis) have revolutionized cancer immunotherapy but also can induce autoimmune hemolytic anemia (AIHA), a severe disease with high mortality. However, the cellular and molecular mechanism(s) of AIHA secondary to ICPi therapy (ICPi-AIHA) are unclear, other than being initiated through decreased checkpoint inhibition. Herein, we report ICPi-AIHA in a novel mouse model that shows similar characteristics of known human ICPi-AIHA (eg, autoantibodies, hemolysis, and increased mortality). During ICPi-AIHA, there is the simultaneous reduction of 2 regulatory T-cell populations (FoxP3+ and Tr1 [type 1 regulatory cells]) and an increase in inflammatory T helper cell 17 (TH17). Moreover, a novel CD39+CD73-FoxP3-CD25- CD4+ T-cell subset (ie, CD39 single positive [CD39SP]) emerges, and early increases in CD39SP predict AIHA development; CD39 is an ectonuclease that breaks down adenosine triphosphate (ATP). Additionally, we found that boosting ATPase activity by injecting recombinant apyrase mitigates AIHA development and significant CD39SP reductions, both suggesting a functional role for CD39 and demonstrating a novel therapeutic approach. Importantly, CD39SP are detectable in multiple mouse models developing AIHA and in patients with AIHA, demonstrating applicability to idiopathic and secondary AIHA. Highlighting broader autoimmunity relevance, ICPi-treated NZB mice experienced accelerated onset and severity of lupus, including AIHA. Moreover, ICPi treatment of healthy B6 animals led to detectable CD39SP and development of autoantibodies against multiple autoantigens including those on red blood cells and platelets. Together, our findings provide further insight into the cellular and molecular mechanisms of ICPi-AIHA, leading to novel diagnostic and therapeutic approaches with translational potential for use in humans being treated with ICPi.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dei Zotti F, Qiu A, D'Agati VD, et al. Mitigation of checkpoint inhibitor-induced autoimmune hemolytic anemia through modulation of purinergic signaling. Blood. 2024. PMID: 39102659. doi:10.1182/blood.2024024230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。